Creating Microbiome Immunotherapeutics
Quorum Innovations is a biopharmaceutical company focused on discovering and developing human microbiome therapeutics. The Company's multiple therapeutic platforms establish Quorum Innovations at the forefront of this exciting scientific frontier.
An Area of Transformational Medicine
The human microbiome, consisting of trillions of microbes, is a human-microbial superorganism. The relationship between the human host and its microbial collective is so vital that the microbiome can be considered another functioning body organ, and is increasingly accepted as having a pivotal role in human health and disease.
Clinically-Driven Drug Discovery
We target clinical entities that are being re-interpreted as dysbiotic states. Our lead product is for atopic dermatitis, the first result of a discovery platform that addresses chronic inflammation and diseases of tissue barrier deficiency.
MiNE™ discovery platform & Probiomic Therapeutics
Our lead candidate is for atopic dermatitis. Beyond AD, we have identified compounds for the treatment of other conditions characterized by chronic inflammation, loss of filaggrin and tissue barrier deficiency. These include allergic rhinitis, dry eye syndrome and eosinophilic esophagitis.
The Microbiome as the Future of Medicine:
Quorum’s mission is to become the global leader in microbiome therapeutics.